Hyderabad-based Laurus Labs receives licence to manufacture 2DG

2DG has been given emergency approval by the Drug Controller General of India (DCGI) for the treatment of Covid-19 patients in the country.

Hyderabad: Hyderabad-based Laurus Labs, a research & development-driven and fully integrated pharmaceutical and biotech company, has received the licence from Defence Research & Development Organisation (DRDO) to manufacture and market 2- Deoxy-D-Glucose (2DG).

2DG has been given emergency approval by the Drug Controller General of India (DCGI) for the treatment of Covid-19 patients in the country. Laurus Labs has already applied with CDSCO for emergency use authorisation (EUA) for 2DG.

---

Laurus over the years has built its capabilities in the areas of bulk drugs for anti-retroviral (ARV), oncology, cardiovascular, anti-diabetics, anti-asthma, and gastroenterology. The company is also in the formulations space catering to North America, Europe, and Low Middle-Income Countries (LMIC). Its manufacturing facilities are approved by major regulatory authorities such as the USFDA, WHO-Geneva, UK-MHRA, etc.

---

Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.

Click to follow Telangana Today Facebook page and Twitter .